Nvidia faces deepening institutional challenges beyond CEO Jensen Huang's departure, with board members rejecting potential reinstatement and regulatory pressure mounting on AI chip exports. For healthcare organizations, this signals potential disruption in GPU procurement timelines and pricing for AI infrastructure supporting clinical decision support, medical imaging analysis, and EHR-integrated ML models. Healthcare systems relying on Nvidia's dominant position in healthcare AI compute should evaluate supply chain redundancy and negotiate longer-term contracts before leadership instability affects delivery schedules. The U.S. regulatory tightening on remote AI access also creates compliance implications for telehealth platforms and cloud-based clinical AI tools that depend on Nvidia's technology stack. Healthcare CIOs should monitor Nvidia's operational continuity and prepare contingency plans for alternative GPU vendors in their AI strategy roadmaps.